37.72 USD
↗ 0.97 (2.65%)LIVE (AS OF 03:27 PM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
Market: OPEN
Roivant Sciences Ltd. Common Shares (ROIV) trades at $37.72 per share. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 26, 2026.
Open?$36.85
High?$37.69
Low?$36.51
Prev. Close?$36.75
Volume?2.7M
Avg. Volume?5.3M
VWAP?$37.00
Rel. Volume?0.51x
Bid / Ask
Bid?$37.15 × 300
Ask?$38.46 × 100
Spread?$1.31
Midpoint?$37.81
Valuation & Ratios
Market Cap?26.5B
Shares Out?722.3M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?6.27
EPS?-$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
26.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?45
Piotroski F-Score?0/9Weak
Altman Z-Score?41.81Safe
Confidence?58%Low
Short InterestHigh
Short % of Float?8.25%Elevated
Short Interest?30.6M
Days to Cover?5.0
Free Float371.0M
Avg Daily Volume6.1M
Settlement Date2026-08-14
Financial Health
Current Ratio?16.72Strong
Quick Ratio?16.72Strong
Cash Ratio?4.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.27FAIR▾
Peers100
S&P29
P/S?3,524.35HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-18.6CHEAP▾
S&P97
EV/Sales?3,358.59HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.3%WEAK▾
S&P10
ROA?-5.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-821063000
Enterprise Value?$25.3B
Fundamentals ratios updated end of day